A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
Trial status:Recruitment Complete
Study Identifier:
GO40558
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
Genentech, Inc.
Recruitment Complete
Trial details
Medical Condition
Study Drug
Phase
Phase 2
Sex
Female & Male
Age
18+
Estimated Trial Date
Jan 2019 - Oct 2025
Protocol summary
This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.
Trial locations
Location
Status
Location
HonorHealth Research Institute ? Bisgrove
Scottsdale, Arizona, United States, 85258
Status
Location
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010
Status
Location
University of California San Diego Moores Cancer Center
La Jolla, California, United States, 92037
Status
Location
The Los Angeles Clinic
Los Angeles, California, United States, 90025
Status
Location
UCSF Comprehensive Cancer Ctr
San Francisco, California, United States, 94158
Status
Location
University of Colorado
Denver, Colorado, United States, 80262
Status